The scientific foundation of this approach is the cholinergic hypothesis, one of the oldest and most extensively studied theories in Alzheimer’s research. It holds that the cognitive decline characteristic of the disease stems largely from the degeneration of cholinergic neurons, particularly in the nucleus basalis of Meynert, a deep brain region critical for attention and learning. When these neurons die, levels of acetylcholine plummet, and the enzyme acetylcholinesterase rapidly degrades what little remains in the synaptic cleft, splitting it into acetate and choline. Existing drugs such as donepezil, rivastigmine, and galantamine work by blocking this enzyme, temporarily boosting acetylcholine signalling. But they offer only symptomatic relief, and their effectiveness fades as cholinergic neurons continue to die.

What makes the new review compelling is its argument that acetylcholinesterase is far more than a passive cleanup enzyme. The authors assemble evidence that the enzyme actively worsens multiple Alzheimer’s pathologies. Through its peripheral anionic site, acetylcholinesterase binds amyloid-beta and accelerates its aggregation into toxic fibrils, forming complexes that are more damaging than amyloid alone. The enzyme is also linked to tau pathology, activating glycogen synthase kinase-3, which drives the hyperphosphorylation of tau protein that disrupts neuronal structure. Oxidative stress increases acetylcholinesterase expression, creating a vicious cycle in which cholinergic decline and cellular damage reinforce each other. Even genetic risk is entangled: the APOE4 allele interacts with butyrylcholinesterase to form complexes that are exceptionally efficient at degrading acetylcholine.

This multifunctional role of the enzyme has inspired a design philosophy known as multitarget-directed ligands. Rather than simply blocking the catalytic active site at the bottom of the enzyme’s deep gorge, modern candidates are engineered to also engage the peripheral anionic site, simultaneously boosting cholinergic signalling and interfering with amyloid aggregation. The review highlights how researchers have achieved this by taking scaffolds borrowed from nature, such as coumarin, xanthone, chalcone, quinoline, and quinazoline, and systematically modifying them through established organic reactions including Williamson ether synthesis, Claisen-Schmidt condensation, and microwave-assisted cyclisation.

The potency figures reported across these studies are striking. A hydrazinyl coumarin derivative synthesized via Hantzsch thiazoline condensation achieved an inhibitory concentration of 0.451 micromolar, outperforming donepezil itself, and significantly improved memory in scopolamine-treated mice. A coumarin-pyridinium bromide salt reached an extraordinary 2 nanomolar potency against acetylcholinesterase while protecting neuronal cells from oxidative damage. Among xanthones, a bis-alkyloxy derivative hit 0.328 micromolar, comparable to the withdrawn drug tacrine, while a xanthone-alkylbenzylamine hybrid reversed memory deficits in an amnesia mouse model at a predicted safe dose of 2500 milligrams per kilogram in rats.

Chalcone derivatives, built from two aromatic rings joined by an alpha-beta unsaturated carbonyl, delivered some of the most impressive numbers in the review. An oxindole-fused chalcone inhibited acetylcholinesterase at 0.10 micromolar and butyrylcholinesterase at 0.30 micromolar, with favourable blood-brain barrier permeability and low predicted toxicity. A pyridine-based chalcone not only inhibited the enzyme at 0.1 micromolar but also blocked 83.58 percent of amyloid-beta aggregation after 48 hours. In the quinazoline family, a mercapto-quinazoline candidate achieved 9.26 nanomolar inhibition, beating donepezil’s 16.43 nanomolar benchmark, and showed significant efficacy in a streptozotocin-induced mouse model of the disease.

Structure-activity relationship analysis reveals the chemical logic underlying these successes. For coumarins, substitution at the seventh position and a short alkyl linker are critical, with longer chains failing to deliver. In xanthones, pyrrolidine and phenyl substitutions enhance activity, and the terminal alkyne linker strengthens binding. Bromine-substituted chalcones bearing pyridine and benzylpiperazine rings show marked potency gains, as do trifluoromethyl and hydroxyl groups on the phenyl ring. For quinazolines, a fluorine atom at the third position of the phenyl ring significantly boosts inhibition, while electron-withdrawing groups and benzylpiperazine moieties improve both enzyme binding and brain penetration.

To place these candidates on a common footing, the authors performed their own molecular docking analysis against two well-characterized acetylcholinesterase crystal structures, PDB entries 1EVE and 4PQE. Using PyRx for scoring and Discovery Studio for visualization, they found that a phenyl-quinoline compound and a quinoline-thiosemicarbazone hybrid achieved the strongest binding energies, at minus 12.6 and minus 12.4 kilocalories per mole respectively. Other leads, including a coumarinyloxy acetohydroxamic derivative and a chromeno xanthone, formed favourable hydrogen bonds and pi-pi stacking interactions with key residues such as TYR337, TYR124, TRP286, and TYR341, suggesting genuine stabilization within the enzyme’s binding pocket rather than mere computational artefact.

The review is candid about the limitations. Most preclinical evidence comes from scopolamine and aluminium chloride-induced animal models, which capture cholinergic dysfunction but not the full complexity of human Alzheimer’s disease. Several candidates have failed clinically due to poor bioavailability, hepatotoxicity, and gastrointestinal side effects, and the historical withdrawal of tacrine for liver toxicity remains a cautionary tale. Clinical trials of cholinergic agents, catalogued from ClinicalTrials.gov, consistently show symptomatic improvement rather than disease modification. The authors argue that future work must move to transgenic models, refine pharmacokinetic profiles, and explore nanocarrier delivery systems such as liposomes and polymeric nanoparticles to improve drug stability and controlled release.

Nevertheless, the convergence of phytochemical inspiration, rational synthetic design, and computational validation represents a genuine shift in how the field approaches acetylcholinesterase. By treating the enzyme as a hub connecting cholinergic failure, amyloid toxicity, tau pathology, oxidative stress, and neuroinflammation, these synthetic modulators aim to do what single-target drugs could not: address several facets of the disease at once. The road from nanomolar enzyme inhibition to a proven, well-tolerated therapy is long, but the review makes a persuasive case that the chemical toolkit for that journey is now richer than ever.

Subject of Research: Synthetic phytochemical-inspired acetylcholinesterase inhibitors as multitarget therapeutic candidates for Alzheimer's disease

Article Title: Synthetic modulators of acetylcholinesterase: mechanistic, SAR, and therapeutic perspectives in Alzheimer’s disease

Article References: Ghose, A., Paidesetty, S. K., Prusty, S. K., Panda, P. K., Pattanaik, S., Pakeeraiah, K., Sahoo, S. S., & Sahu, P. K. (2026). Synthetic modulators of acetylcholinesterase: mechanistic, SAR, and therapeutic perspectives in Alzheimer’s disease. Journal of Saudi Chemical Society, 30(2), Article 25. https://doi.org/10.1007/s44442-026-00073-x

Image Credits: AI Generated

DOI: 10.1007/s44442-026-00073-x

Keywords: Alzheimer's disease, acetylcholinesterase inhibitors, multitarget-directed ligands, coumarin, chalcone, xanthone, quinoline, quinazoline, structure-activity relationships, molecular docking, neuroinflammation, amyloid-beta